THE COMPARISON OF MIRROR-WRITING BETWEEN DEAFMUTES AND NORMAL CHILDREN

本文选择了聋哑右利儿童113人和正常右利儿童133人,用八种书写方式书写八个汉字和阿拉伯数字1-10。结果表明;聋哑一年级学生出现的镜像书写人均人次比正常幼儿园儿童少,而其它年级间的比较则无显著性差异;聋哑9&mdash;10岁儿童比同年龄组的正常儿童所出现的镜像书写人次多,而在11&mdash;12岁组则无显著性差异。通过分析,提出了镜像书写可能存在两个关键期的假说,一是字体熟练程度的关键期,一般在受教育的最初1&mdash;2年;另一个是大脑对镜像书写的调节和控制关键期,一般在6岁左右</p

MIRROR WRITING AT STROKE LEVEL

本研究选择60名右利大学生(男女各半)为被试,在笔划水平上对十四种不同书写方式下快速书写时所出现的自发性镜像书写进行了研究。所有被试随机分为人数相等的实验、对照两组,组内男女各半。对实验组加以注意干扰。书写内容是十个阿拉伯数字(0&mdash;9)及十三个汉字组成的一句话。本研究结果表明:注意干扰、感觉的反馈调节,书写内容的特点是影响镜像书写出现的重要因素。作者在分析国内外有关镜像书写工作的基础上,进一步提出了&ldquo;稳态系统&rdquo;理论。</p

EFFECTS OF PSYCHOLOGICAL FACTORS ON THE DEVELOPMENT OF STOMACH CANC

使用Ｃ型行为特征问卷、生活事件量表和ＲＢＣ－Ｃ３ｂＲ、ＲＢＣ－ＩＣ、ＲＣＩＡ、ＣＩＣ和Ｃ３等免疫功能的检测，调查和检测了３０名胃癌患者和５０名健康者。结果表明：（１）胃癌组比健康组在焦虑、抑郁、愤怒内泄、控制等方面得分高，在愤怒外泄、乐观、社会支持等方面得分低；（２）胃癌患者在确诊前８年内有７６％的患者遇到生活事件，在确诊前３年内有６２％的患者遇到生活事件；（３）胃癌组ＲＢＣ－Ｃ３ｂＲ含量低，ＲＣＩＡ含量和ＣＩＣ水平上升。初步结论：胃癌的发生与患者的一些行为特点有关，主要是抑郁并不表达愤怒；生活事件可作为应激源诱发胃癌；其机制可能与免疫功能有关。&nbsp;</p

CHILDREN'S MIRROR WRITING

本实验选择了幼儿园大班,小学一、三、五年级的5&mdash;12岁右利儿童133人,用八种书写方式书写自己的姓名、阿拉伯数字1&mdash;10和八个汉字,同时检查了儿童的定向能力。结果表明:随着年龄的增大,镜像书写出现的人次和数目减少;自左往右的习惯方向书写所出现的镜像人次和数目比自右往左的非习惯方向少;左手出现镜像书写比右手多;双手同时书写比单手出现的镜像书写多;有空间定向力的比仅有自身定向和无定向力的人出现的镜像书写少。本文验证了镜像书写形成的传统假说后,进一步提出了熟练理论:随着对汉字和数字的认知与视-书写运动图式的牢固掌握,镜像字体的出现就逐渐减少,并认为镜像书写存在着一个复杂的机制,是受多因素控制的。</p

Aripiprazole versus other atypical antipsychotics for schizophrenia

BACKGROUND: In most western industrialised countries, second generation (atypical) antipsychotics are recommended as first line drug treatments for people with schizophrenia. In this review we specifically examine how the efficacy and tolerability of one such agent - aripiprazole - differs from that of other comparable second generation antipsychotics. OBJECTIVES: To evaluate the effects of aripiprazole compared with other atypical antipsychotics for people with schizophrenia and schizophrenia-like psychoses. SEARCH METHODS: We searched the Cochrane Schizophrenia Group Trials Register (November 2011), inspected references of all identified studies for further trials, and contacted relevant pharmaceutical companies, drug approval agencies and authors of trials for additional information. SELECTION CRITERIA: We included all randomised clinical trials (RCTs) comparing aripiprazole (oral) with oral and parenteral forms of amisulpride, clozapine, olanzapine, quetiapine, risperidone, sertindole, ziprasidone or zotepine for people with schizophrenia or schizophrenia-like psychoses. DATA COLLECTION AND ANALYSIS: We extracted data independently. For dichotomous data we calculated risk ratios (RR) and their 95% confidence intervals (CI) on an intention-to-treat basis based on a random-effects model. Where possible, we calculated illustrative comparative risks for primary outcomes. For continuous data, we calculated mean differences (MD), again based on a random-effects model. We assessed risk of bias for each included study. MAIN RESULTS: We included 12 trials involving 6389 patients. Aripiprazole was compared to olanzapine, risperidone and ziprasidone. All trials were sponsored by an interested drug manufacturer. The overall number of participants leaving studies early was 30% to 40%, limiting validity (no differences between groups).When compared with olanzapine no differences were apparent for global state (no clinically important change: n = 703, 1 RCT, RR short-term 1.00 95% CI 0.81 to 1.22; n = 317, 1 RCT, RR medium-term 1.08 95% CI 0.95 to 1.22) but mental state tended to favour olanzapine (n = 1360, 3 RCTs, MD total Positive and Negative Syndrome Scale (PANSS) 4.68 95% CI 2.21 to 7.16). There was no significant difference in extrapyramidal symptoms (n = 529, 2 RCTs, RR 0.99 95% CI 0.62 to 1.59) but fewer in the aripiprazole group had increased cholesterol levels (n = 223, 1 RCT, RR 0.32 95% CI 0.19 to 0.54) or weight gain of 7% or more of total body weight (n = 1095, 3 RCTs, RR 0.39 95% CI 0.28 to 0.54).When compared with risperidone, aripiprazole showed no advantage in terms of global state (n = 384, 2 RCTs, RR no important improvement 1.14 95% CI 0.81 to 1.60) or mental state (n = 372, 2 RCTs, MD total PANSS 1.50 95% CI -2.96 to 5.96).One study compared aripiprazole with ziprasidone (n = 247) and both the groups reported similar change in the global state (n = 247, 1 RCT, MD average change in Clinical Global Impression-Severity (CGI-S) score -0.03 95% CI -0.28 to 0.22) and mental state (n = 247, 1 RCT, MD change PANSS -3.00 95% CI -7.29 to 1.29).When compared with any one of several new generation antipsychotic drugs the aripiprazole group showed improvement in global state in energy (n = 523, 1 RCT, RR 0.69 95% CI 0.56 to 0.84), mood (n = 523, 1 RCT, RR 0.77 95% CI 0.65 to 0.92), negative symptoms (n = 523, 1 RCT, RR 0.82 95% CI 0.68 to 0.99), somnolence (n = 523, 1 RCT, RR 0.80 95% CI 0.69 to 0.93) and weight gain (n = 523, 1 RCT, RR 0.84 95% CI 0.76 to 0.94). Significantly more people given aripiprazole reported symptoms of nausea (n = 2881, 3 RCTs, RR 3.13 95% CI 2.12 to 4.61) but weight gain (7% or more of total body weight) was less common in people allocated aripiprazole (n = 330, 1 RCT, RR 0.35 95% CI 0.19 to 0.64). Aripiprazole may have value in aggression but data are limited. This will be the focus of another review. AUTHORS' CONCLUSIONS: Information on all comparisons are of limited quality, are incomplete and problematic to apply clinically. Aripiprazole is an antipsychotic drug with a variant but not absent adverse effect profile. Long-term data are sparse and there is considerable scope for another update of this review as new data emerges from the many Chinese studies as well as from ongoing larger, independent pragmatic trials